Does the media refer more to URGN or OVID?

In the previous week, Urogen Pharma had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 10 mentions for Urogen Pharma and 6 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.77 beat Urogen Pharma's score of 0.69 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, HCM or OVID?

HUTCHMED has higher revenue and earnings than Ovid Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.08 $456.91M N/A N/A Ovid Therapeutics $7.25M 72.46 -$17.41M -$0.31 N/A

Does the media prefer HCM or OVID?

In the previous week, Ovid Therapeutics had 1 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Ovid Therapeutics and 5 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.81 beat Ovid Therapeutics' score of 0.77 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OVID or PRGO more profitable?

Perrigo has a net margin of -41.85% compared to Ovid Therapeutics' net margin of -240.11%. Perrigo's return on equity of 11.25% beat Ovid Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics -240.11% -23.64% -20.52% Perrigo -41.85% 11.25% 4.08%

Does the media favor OVID or PRGO?

In the previous week, Ovid Therapeutics had 4 more articles in the media than Perrigo. MarketBeat recorded 6 mentions for Ovid Therapeutics and 2 mentions for Perrigo. Perrigo's average media sentiment score of 1.00 beat Ovid Therapeutics' score of 0.77 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GHRS or OVID?

In the previous week, Ovid Therapeutics had 4 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Ovid Therapeutics and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Ovid Therapeutics' score of 0.77 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OVID or CMPS?

In the previous week, Compass Pathways had 8 more articles in the media than Ovid Therapeutics. MarketBeat recorded 14 mentions for Compass Pathways and 6 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.77 beat Compass Pathways' score of 0.47 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ovid Therapeutics (OVID) Competitors

$2.69 +0.06 (+2.28%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.66 -0.03 (-1.12%)

As of 09/11/2026 07:30 PM Eastern

Compare

OVID vs. URGN, HCM, PRGO, GHRS, and CMPS

Should you buy Ovid Therapeutics stock or one of its competitors? Ovid Therapeutics's main competitors and comparable companies include Urogen Pharma (URGN), HUTCHMED (HCM), Perrigo (PRGO), GH Research (GHRS), and Compass Pathways (CMPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ovid Therapeutics compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and Ovid Therapeutics (NASDAQ:OVID) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Urogen Pharma has a net margin of -51.73% compared to Ovid Therapeutics' net margin of -240.11%. Urogen Pharma's return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

Urogen Pharma currently has a consensus target price of $52.38, suggesting a potential upside of 23.79%. Ovid Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 123.05%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Urogen Pharma had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 10 mentions for Urogen Pharma and 6 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.77 beat Urogen Pharma's score of 0.69 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Ovid Therapeutics has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	18.84	-$153.49M	-$1.98	N/A
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A

Summary

Ovid Therapeutics beats Urogen Pharma on 10 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Ovid Therapeutics (NASDAQ:OVID) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

HUTCHMED has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. HUTCHMED's return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

HUTCHMED currently has a consensus price target of $14.87, indicating a potential upside of 15.96%. Ovid Therapeutics has a consensus price target of $6.00, indicating a potential upside of 123.05%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

HUTCHMED has higher revenue and earnings than Ovid Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.08	$456.91M	N/A	N/A
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A

HUTCHMED has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, Ovid Therapeutics had 1 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Ovid Therapeutics and 5 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.81 beat Ovid Therapeutics' score of 0.77 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ovid Therapeutics beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does Ovid Therapeutics compare to Perrigo?

Ovid Therapeutics (NASDAQ:OVID) and Perrigo (NYSE:PRGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Perrigo has a net margin of -41.85% compared to Ovid Therapeutics' net margin of -240.11%. Perrigo's return on equity of 11.25% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-23.64%	-20.52%
Perrigo	-41.85%	11.25%	4.08%

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ovid Therapeutics has higher earnings, but lower revenue than Perrigo. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A
Perrigo	$4.14B	0.46	-$1.43B	-$12.51	N/A

In the previous week, Ovid Therapeutics had 4 more articles in the media than Perrigo. MarketBeat recorded 6 mentions for Ovid Therapeutics and 2 mentions for Perrigo. Perrigo's average media sentiment score of 1.00 beat Ovid Therapeutics' score of 0.77 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 123.05%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 41.50%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Ovid Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ovid Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Summary

Ovid Therapeutics beats Perrigo on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

56.9% of GH Research shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GH Research has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. GH Research's return on equity of -20.86% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

GH Research currently has a consensus target price of $45.00, suggesting a potential upside of 65.44%. Ovid Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 123.05%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Ovid Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A

In the previous week, Ovid Therapeutics had 4 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Ovid Therapeutics and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Ovid Therapeutics' score of 0.77 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

Ovid Therapeutics beats GH Research on 9 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Compass Pathways?

Ovid Therapeutics (NASDAQ:OVID) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Ovid Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 123.05%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 62.77%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Pathways has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -23.64% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-23.64%	-20.52%
Compass Pathways	N/A	-49.63%	-13.08%

In the previous week, Compass Pathways had 8 more articles in the media than Ovid Therapeutics. MarketBeat recorded 14 mentions for Compass Pathways and 6 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.77 beat Compass Pathways' score of 0.47 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market.

Ovid Therapeutics has higher revenue and earnings than Compass Pathways. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ovid Therapeutics beats Compass Pathways on 9 of the 15 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$513.63M	$12.44B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-8.68	799.75	275.24	25.29
Price / Sales	72.46	763.36	655.99	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	2.69	10.39	10.33	6.20
Net Income	-$17.41M	$2.85B	$3.50B	$358.50M
7 Day Performance	-3.93%	-3.61%	-3.32%	-2.35%
1 Month Performance	2.67%	0.86%	-0.41%	-2.77%
1 Year Performance	113.49%	3.47%	19.21%	7.63%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	2.6262 of 5 stars	$2.69 +2.3%	$6.00 +123.0%	+115.2%	$513.63M	$7.25M	N/A	60	News Coverage Analyst Forecast Gap Up
URGN Urogen Pharma	2.974 of 5 stars	$43.21 +0.3%	$50.38 +16.6%	+119.8%	$2.11B	$109.79M	N/A	200	Analyst Forecast Gap Up
HCM HUTCHMED	2.143 of 5 stars	$12.02 -0.9%	$14.87 +23.7%	-21.7%	$2.10B	$548.51M	N/A	1,796	Analyst Upgrade
PRGO Perrigo	3.8075 of 5 stars	$14.45 -1.3%	$19.33 +33.8%	-39.3%	$2.01B	$4.25B	N/A	8,100	Positive News
GHRS GH Research	2.6272 of 5 stars	$27.65 +2.5%	$45.00 +62.8%	+117.9%	$1.90B	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. URGN, HCM, PRGO, GHRS, and CMPS

How does Ovid Therapeutics compare to Urogen Pharma?

Summary

How does Ovid Therapeutics compare to HUTCHMED?

Summary

How does Ovid Therapeutics compare to Perrigo?

Summary

How does Ovid Therapeutics compare to GH Research?

Summary

How does Ovid Therapeutics compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. URGN, HCM, PRGO, GHRS, and CMPS

How does Ovid Therapeutics compare to Urogen Pharma?

Is URGN or OVID more profitable?

Do analysts recommend URGN or OVID?

Do institutionals & insiders hold more shares of URGN or OVID?

Does the media refer more to URGN or OVID?

Which has more risk and volatility, URGN or OVID?

Which has stronger valuation and earnings, URGN or OVID?

Summary

How does Ovid Therapeutics compare to HUTCHMED?

Do insiders and institutionals have more ownership in HCM or OVID?

Is HCM or OVID more profitable?

Do analysts recommend HCM or OVID?

Which has better valuation and earnings, HCM or OVID?

Which has more risk & volatility, HCM or OVID?

Does the media prefer HCM or OVID?

Summary

How does Ovid Therapeutics compare to Perrigo?

Is OVID or PRGO more profitable?

Do insiders & institutionals believe in OVID or PRGO?

Which has stronger valuation & earnings, OVID or PRGO?

Does the media favor OVID or PRGO?

Do analysts rate OVID or PRGO?

Which has more risk & volatility, OVID or PRGO?

Summary

How does Ovid Therapeutics compare to GH Research?

Do institutionals and insiders hold more shares of GHRS or OVID?

Is GHRS or OVID more profitable?

Do analysts recommend GHRS or OVID?

Which has stronger earnings & valuation, GHRS or OVID?

Does the media prefer GHRS or OVID?

Which has more volatility and risk, GHRS or OVID?

Summary

How does Ovid Therapeutics compare to Compass Pathways?

Do analysts rate OVID or CMPS?

Is OVID or CMPS more profitable?

Does the media favor OVID or CMPS?

Which has more volatility and risk, OVID or CMPS?

Which has higher valuation and earnings, OVID or CMPS?

Do institutionals & insiders believe in OVID or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools